Abstract:As a key component in combination therapy for acquired immunodeficiency syndrome (AIDS), non-nucleoside reverse transcriptase inhibitors (NNRTIs) have been proven to be an essential way in stopping HIV-1 replication. In the present work, in silico studies were conducted on a series of 119 NNRTIs, including 1-(2-hydroxyethoxymethyl)-6-(phenylthio)thymine (HEPT) and dihydroalkoxybenzyloxopyrimidine (DABO) derivatives by using the comparative molecular field analysis (CoMFA), comparative molecular similarity indices analysis (CoMSIA), docking simulations and molecular dynamics (MD). The statistical results of the optimal model, the ligand-based CoMSIA one (Q 2 = 0.48, R ncv 2 =0.847, R pre 2 = 0.745) validates its satisfactory predictive capacity both internally and externally. The contour maps, docking and MD results correlate well with each other, drawing conclusions as follows: 1) Compounds with bulky substituents in position-6 of ring A, hydrophobic groups around position- 1, 2, 6 are preferable to the biological activities; 2) Two hydrogen bonds between RT inhibitor and the Tyr 318, Lys 101 residues, respectively, and a π-π bond between the inhibitor and Trp 188 are formed and crucial to the orientation of the active conformation of the molecules; 3) The binding pocket is essentially hydrophobic, which are determined by residues such as Trp 229, Tyr 318, Val 179, Tyr 188 and Val 108, and hydrophobic substituents may bring an improvement to the biological activity; 4) DABO and HEPT derivatives have different structures but take a similar mechanism to inhibit RT. The potency difference between two isomers in HEPTs can be explained by the distinct locations of the 6-naphthylmethyl substituent and the reasons are explained in details. All these results could be employed to alter the structural scaffold in order to develop new HIV-1 RT inhibitors that have an improved biological property. To the best of our knowledge, this is the first report on 3D-QSAR modeling of this series of HEPT and DABO NNRTs. The QSAR model and the information derived, we hope, will be of great help in presenting clear guidelines and accurate activity predictions for newly designed HIV-1 reverse transcriptase (RT) inhibitor.

Docking and field-based QSAR studies of S-DABOs as HIV-1 reverse transcriptase inhibitors

3D-QSAR Studies of S-DABO Derivatives as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors

Docking Field-Based QSAR and Pharmacophore Studies on the Substituted Pyrimidine Derivatives Targeting HIV-1 Reverse Transcriptase

Docking, Molecular Dynamics and Quantitative Structure-Activity Relationship Studies for HEPTs and DABOs As HIV-1 Reverse Transcriptase Inhibitors

Molecular modeling studies of dihydro-alkyloxy-benzyl-oxopyrimidines (DABOs) as non-nucleoside inhibitors of HIV-1 reverse transcriptase using 3D-QSAR, Topomer CoMFA and molecular docking simulations

Receptor-based Molecular Designs of DABO Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors

HQSAR Studies on S-DABO Derivatives As HIV-1 Reverse Transcriptase Inhibitors

3D-QSAR Analysis of a Series of S-DABO Derivatives As Anti-Hiv Agents by CoMFA and CoMSIA

QSAR Studies on 6-（1-naphthylmethyl） Substituted S-DABO Derivatives As Novel Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors

Receptor- and Ligand-Based 3D-QSAR Study for a Series of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors.

3D-Qsar and Docking Studies on Piperidine-Substituted Diarylpyrimidine Analogues As Hiv-1 Reverse Transcriptase Inhibitors

3D-QSAR for HIV-1 reverse transcriptase inhibitors

Molecular Docking and 3D-QSAR Research of Diaryltriazines Derivatives as HIV-1 Reverse Transcriptase Inhibitors

Towards New C6-rigid S-DABO HIV-1 Reverse Transcriptase Inhibitors: Synthesis, Biological Investigation and Molecular Modeling Studies

Evaluation of Novel HIV-1 Protease Inhibitors with DRV-resistance by Utilizing 3D-QSAR Molecular Docking and Molecular Dynamics Simulation

3D-QSAR, Molecular Docking, and Molecular Dynamics Simulation of a Novel Thieno[3,4-D]pyrimidine Inhibitor Targeting Human Immunodeficiency Virus Type 1 Reverse Transcriptase

Three dimensional quantitative structure-activity relationship of DATA analogues as HIV-1 reverse transcriptase inhibitors

Expansion of the S-CN-DABO Scaffold to Exploit the Impact on Inhibitory Activities Against the Non-Nucleoside HIV-1 Reverse Transcriptase.

3D-QSAR Studies on DATAs and DAPYs for HIV-RT Inhibitors using CoMFA and CoMSIA Approaches

Synthesis and Biological Evaluation of New Conformationally Restricted S-DABO Hybrids As Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase

3D-QSAR Modeling, Surflex Docking and Reverse Docking Studies of Diketo-Acid Derivatives as Potent Integrase/Rnase H Inhibitors